Home » Stocks » IONS

Ionis Pharmaceuticals, Inc. (IONS)

Stock Price: $36.54 USD -0.79 (-2.12%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $36.70 +0.16 (0.44%) May 7, 6:31 PM
Market Cap 5.41B
Revenue (ttm) 707.50M
Net Income (ttm) -492.93M
Shares Out 140.77M
EPS (ttm) -3.59
PE Ratio n/a
Forward PE 90.91
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $36.54
Previous Close $37.33
Change ($) -0.79
Change (%) -2.12%
Day's Open 37.83
Day's Range 36.37 - 39.34
Day's Volume 2,696,020
52-Week Range 36.03 - 64.37

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.

2 days ago - Zacks Investment Research

CARLSBAD, Calif., May 6, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in virtual fireside chats at the following investor conferences:...

2 days ago - PRNewsWire

CARLSBAD, Calif., May 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2021 virtual Annual Meeting of Stockholders followed by a genera...

3 days ago - PRNewsWire

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -33.33% and -16.06%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

3 days ago - Zacks Investment Research

CARLSBAD, Calif., May 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter of 2021 and recent business highlights.

3 days ago - PRNewsWire

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

CARLSBAD, Calif., April 21, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, May 5 th at 11:30 a.m.

2 weeks ago - PRNewsWire

CARLSBAD, Calif., April 20, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced it has initiated a pivotal clinical study of ION373 in patients with Alexander disease, a rare...

2 weeks ago - PRNewsWire

We believe that Ionis Pharmaceuticals stock, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, is a good buying opportunity at the present time. IONS stock trad...

2 weeks ago - Forbes

CARLSBAD, Calif., April 8, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $550.0 million aggregate principal amount of 0% Convertible Senior Notes due 202...

1 month ago - PRNewsWire

Ionis Pharmaceuticals Inc (NASDAQ: IONS) said it expanded its distribution agreement with Swedish Orphan Biovitrum AB (“Sobi”) for Tegsedi in North America. Tegsedi is indicated for polyneuropathy (a co...

Other stocks mentioned: AKCA
1 month ago - Benzinga

CARLSBAD, Calif., April 6, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggreg...

1 month ago - PRNewsWire

NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised ...

1 month ago - PRNewsWire

CARLSBAD, Calif., April 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of a Phase 3 clinical trial of ION363 in patients with amyotrophic lateral scler...

1 month ago - PRNewsWire

NEW YORK, March 30, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS).  Such investors are advise...

1 month ago - PRNewsWire

Ionis Pharmaceuticals Inc (NASDAQ: IONS) has announced data from a Phase 2 study evaluating IONIS-PKK-LRx in patients with hereditary angioedema (HAE). The study met its primary and secondary endpoints,...

1 month ago - Benzinga

CARLSBAD, Calif., March 29, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that data from a Phase 2 clinical study of IONIS-PKK-LRx met its primary and secondary endpoin...

1 month ago - PRNewsWire

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

CARLSBAD, Calif., March 26, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that management will participate in virtual fireside...

1 month ago - PRNewsWire

Cathie Wood's Ark Invest continues to add more shares to its holdings with it picking out a few companies worth noting on Wednesday. The post DDD, AONE, RAVN, ION: 4 Stocks That Cathie Wood's ARK Funds ...

Other stocks mentioned: AONE, DDD, RAVN
1 month ago - InvestorPlace

The biotech's partner is stopping a late-stage clinical trial for a Huntington's disease treatment.

1 month ago - The Motley Fool

Ionis (IONS) stock sinks as partner Roche stops dosing in a late-stage study on tominersen in Huntington's disease.

Other stocks mentioned: RHHBY
1 month ago - Zacks Investment Research

Roche Holdings AG (OTCMKTS: RHHBY) has halted dosing for its Phase 3 study of tominersen, an antisense drug targeting the huntingtin protein and a mutant variant. Roche is calling off the study after an...

1 month ago - Benzinga

Every night, Cathie Wood's Ark Investment Management sends out an email listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have been known to cause cer...

Other stocks mentioned: DDD, DE
1 month ago - Benzinga

CARLSBAD, Calif., March 22, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tomin...

1 month ago - PRNewsWire

In December 2020 we talked about how Ionis Pharmaceuticals stock seems to be oversold, and since then the stock has seen a 15% rise to levels of $54 currently. However, the company's lackluster Q4 resul...

2 months ago - Forbes

CARLSBAD, Calif., March 1, 2021 /PRNewswire/ -- Ionis Pharmaceuticals (NASDAQ: IONS) today announced that the company has launched a new grant program that provides funding to U.S.-based researchers who...

2 months ago - PRNewsWire

Ionis (IONS) Q4 adjusted earnings decline year over year. The company issues guidance for 2021.

2 months ago - Zacks Investment Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -1116.67% and 9.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share fell 39.10% over the past year to $0.81, which beat the esti...

2 months ago - Benzinga

CARLSBAD, Calif., Feb. 24, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the fourth quarter of 2020 and recent business highlights. "Last year,...

2 months ago - PRNewsWire

CARLSBAD, Calif., Feb. 19, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that management will participate in a virtual firesid...

2 months ago - PRNewsWire

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

CARLSBAD, Calif., Feb. 11, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 24th at 9:00 a.m. Eastern Time to discu...

2 months ago - PRNewsWire

Our theme of Out Of Favor Health Care Stocks includes health care stocks that have witnessed strong Revenue growth and improving fundamentals over the last few years but have underperformed in 2020, on ...

Other stocks mentioned: NBIX, VERX
3 months ago - Forbes

CARLSBAD, Calif., Jan. 7, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the appointment of Eugene Schneider, M.D., as executive vice president and chief clinical develo...

4 months ago - PRNewsWire

CARLSBAD, Calif., Jan. 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia, Ph.D., chief executive officer, w...

4 months ago - PRNewsWire

Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over 2020, part...

Other stocks mentioned: ALKS, BMRN
4 months ago - Forbes

CARLSBAD, Calif., Dec. 17, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that its founder and executive chairman Stanley T. Cr...

4 months ago - PRNewsWire

CARLSBAD, Calif., Dec. 8, 2020 /PRNewswire/ -- At its Investor Day yesterday, Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) highlighted the company's significant achievements in 2020 and outlined its strat...

4 months ago - PRNewsWire

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will participate in a virtual fireside ch...

5 months ago - PRNewsWire

CARLSBAD, Calif., Dec. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of the Phase 3 BALANCE study for AKCEA-APOCIII-LRx in adult patients with familia...

5 months ago - PRNewsWire

CARLSBAD, Calif., Dec. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live investor day webcast on Monday, December 7th at 11:00 a.m. Eastern Time...

5 months ago - PRNewsWire

CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION44...

5 months ago - PRNewsWire

CARLSBAD, Calif., Nov. 23, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antisens...

5 months ago - PRNewsWire

CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that new data for ION449, an investigational antisense medicine designed to reduce plasma level...

5 months ago - PRNewsWire

CARLSBAD, Calif., Nov. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the upcoming presentations of clinical and non-clinical data for several of its investigationa...

5 months ago - PRNewsWire

CARLSBAD, Calif., Nov. 10, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that accomplished Ionis scientists will highlight the company's pioneering advancements in rese...

5 months ago - PRNewsWire

CARLSBAD, Calif., Nov. 9, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the fo...

5 months ago - PRNewsWire

About IONS

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclero... [Read more...]

Industry
Biotechnology
IPO Date
May 17, 1991
CEO
Brett Monia
Employees
757
Stock Exchange
NASDAQ
Ticker Symbol
IONS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 23 analysts, the average rating for IONS stock is "Buy." The 12-month stock price forecast is 57.53, which is an increase of 57.44% from the latest price.

Price Target
$57.53
(57.44% upside)
Analyst Consensus: Buy